175402-07-0

Upstream product

• 6068-72-0 4-cyanobenzoyl chlorIde 
• 536-25-4 methyl 3-amino-4-hydroxybenzoate 
• 619-65-8 4-cyanobenzoic Acid 

Downstream Products

• 175402-19-4 (S)-3-{[2-(4-Carbamimidoyl-phenyl)-benzooxazole-5-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid methyl ester 
• 175402-26-3 (S)-3-{[2-(4-Cyano-phenyl)-benzooxazole-5-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid methyl ester 
• 175402-17-2 (S)-2-Butoxycarbonylamino-3-{[2-(4-carbamimidoyl-phenyl)-benzooxazole-5-carbonyl]-amino}-propionic acid methyl ester 
• 175402-13-8 (S)-2-Butoxycarbonylamino-3-{[2-(4-cyano-phenyl)-benzooxazole-5-carbonyl]-amino}-propionic acid methyl ester 
• 175402-05-8 2-(4-Cyano-phenyl)-benzooxazole-5-carboxylic acid 

Relevant academic research and scientific papers

BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY

A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

Design, synthesis and in vitro activities of a series benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors

A potent centrally constrained series of benzimidazole and benzoxazole glycoprotein IIb/IIIa inhibitors has been discovered based on the solution conformation of a cyclic RGD-containing peptide, DMP 728. The high potency of this series of compounds in the inhibition of platelet aggregation requires a benzamidine as the basic moiety and an α-carbamate or sulfonamide substituted β-alanine as the acidic moiety.